The pharmaceutical market in Europe is expected to grow at a compounded annual growth rate (CAGR) of more than 6 percent during 2010-2012, according to market research and information analysis firm RNCOS.

Evotec, a developer of novel small molecule drugs,  has entered into a collaboration with Active Biotech to identify small molecule modulators of a priority biological target selected by Active Bio-tech, involved in immune disorders and cancer.

Roche Diagnostics has purchased assets from BioMicro Systems, a developer of biological research products, for all products associated with the Roche NimbleGen microarray workflow.

Neurologix, a clinical-stage biotechnology company, has appointed Clark Johnson as its new president and CEO. Mr Johnson was a founder of the company and has served on its board of directors since the company’s inception.

Nabi Biopharmaceuticals has reported a net income of $1.11m, or $0.02 per diluted share, for the fourth quarter ended December 26, 2009, compared to a net loss of $4.74m, or $0.09 per diluted share, for the comparable period in 2008.

The global influenza market has been growing at a very healthy rate for the past few years despite the high entry barriers to the influenza vaccine market, such as biological manufacturing know-how and complex public and private business interrelationships, according to research firm RNCOS.

Abbott and Facet Biotech have signed a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid-stage pharmaceutical pipeline. The acquisition brings access to biologics in two key therapeutic areas, immunology and oncology.

The US Food and Drug Administration (FDA) has approved Allergan's Botox (onabotulinumtoxinA) for the treatment of increased muscle stiffness in the elbow, wrist and fingers in adults with upper limb spasticity.

Nabi Biopharmaceuticals has closed an exclusive option and license agreement for NicVAX (Nicotine Conjugate Vaccine), dated November 13, 2009, with GlaxoSmithKline Biologicals (GSK).

Opexa Therapeutics, a developer of patient-specific cellular therapies for the treatment of autoimmune diseases, has reported a net loss of $1.43m, or $0.11 per diluted share, for the full year ended December 31, 2009, compared to $11.85m, or $1.12 per diluted share, for the year ago period.